Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the Board of ....
BAYERCROP · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Bayer CropScience's Board approved unaudited Q2 and H1 FY26 results (ended September 30, 2025) and declared an interim dividend of Rs. 90 per equity share, totaling about Rs. 4,045 million, payable December 3, 2025 to shareholders on record by November 14, 2025. Q2 revenue from operations came in at Rs. 15,534 million, down roughly 10.6% year-on-year from Rs. 17,382 million, though H1 revenue still grew about 2.9% to Rs. 34,680 million. Q2 profit after tax rose about 12% to Rs. 1,527 million, lifting H1 PAT to Rs. 4,314 million versus Rs. 3,905 million in the prior year period (up ~10.5%). H1 EPS improved to Rs. 95.99 from Rs. 86.89. Statutory auditors Deloitte Haskins & Sells LLP issued a clean limited review report with no qualifications, while H1 operating cash flow remained negative at Rs. (349) million, though it improved from Rs. (856) million a year earlier.
A strong interim dividend and steady profit growth are positives for shareholders, but the Q2 revenue dip and continued negative operating cash flow are watchpoints that could weigh on near-term sentiment.